JP Morgan Chase
BDTX icon

JP Morgan Chase’s Black Diamond Therapeutics BDTX Stock Holding History

JP Morgan Chase’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.2K Buy
29,242
+24,604
+530% +$60.2K ﹤0.01% 6412
2026
Q1 		$9.41K Sell
4,638
-2,361
-34% -$5.62K ﹤0.01% 6756
2025
Q4 		$17K Buy
6,999
+6,697
+2,218% +$23.7K ﹤0.01% 6544
2025
Q3 		$1.15K Buy
+302
New +$883 ﹤0.01% 6978
2025
Q2 		– Sell
-20,248
Closed -$31.4K – 7079
2025
Q1 		$31.4K Buy
20,248
+1,319
+7% +$2.77K ﹤0.01% 6024
2024
Q4 		$40.5K Buy
18,929
+1,355
+8% +$3.88K ﹤0.01% 6090
2024
Q3 		$76.4K Buy
17,574
+1,657
+10% +$9.02K ﹤0.01% 5815
2024
Q2 		$74.2K Buy
15,917
+6,428
+68% +$34.5K ﹤0.01% 5682
2024
Q1 		$48.1K Sell
9,489
-812,145
-99% -$3.27M ﹤0.01% 5961
2023
Q4 		$2.31M Sell
821,634
-285,949
-26% -$671K ﹤0.01% 3729
2023
Q3 		$3.18M Buy
1,107,583
+27,524
+3% +$101K ﹤0.01% 3182
2023
Q2 		$5.45M Buy
1,080,059
+1,079,507
+195,563% +$2.2M ﹤0.01% 2792
2023
Q1 		$1K Hold
552
– – ﹤0.01% 6489
2022
Q4 		$1K Sell
552
-1,474
-73% -$2.65K ﹤0.01% 6376
2022
Q3 		$3K Buy
2,026
+514
+34% +$1.58K ﹤0.01% 6176
2022
Q2 		$4K Sell
1,512
-258,960
-99% -$602K ﹤0.01% 6192
2022
Q1 		$723K Buy
260,472
+62,877
+32% +$230K ﹤0.01% 4473
2021
Q4 		$1.05M Sell
197,595
-14,656
-7% -$102K ﹤0.01% 4346
2021
Q3 		$1.79M Sell
212,251
-67,253
-24% -$664K ﹤0.01% 3870
2021
Q2 		$3.41M Sell
279,504
-72,356
-21% -$1.43M ﹤0.01% 3370
2021
Q1 		$8.54M Sell
351,860
-6,993
-2% -$189K ﹤0.01% 2509
2020
Q4 		$11.5M Buy
358,853
+154,911
+76% +$5.09M ﹤0.01% 2098
2020
Q3 		$6.2M Buy
203,942
+130,245
+177% +$3.96M ﹤0.01% 2387
2020
Q2 		$3.11M Sell
73,697
-26,689
-27% -$982K ﹤0.01% 2809
2020
Q1 		$2.5M Buy
+100,386
New +$3.06M ﹤0.01% 2792

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

JP Morgan Chase's BDTX Position: Q2 2026 in Review

JP Morgan Chase increased its Black Diamond Therapeutics (BDTX) stake by 530% in Q2 2026, buying an estimated $60.2K and bringing the position to 29,242 shares worth $51.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6412.

JP Morgan Chase first reported a position in BDTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $11.5M in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • JP Morgan Chase held 29,242 shares of Black Diamond Therapeutics worth $51.2K as of Q2 2026.
  • JP Morgan Chase bought 24,604 Black Diamond Therapeutics shares in Q2 2026, an estimated $60.2K.
  • Black Diamond Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6412 holding.
  • JP Morgan Chase first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • JP Morgan Chase's Black Diamond Therapeutics position peaked at $11.5M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.